NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) has announced its successful return to compliance with Nasdaq’s minimum stockholders’ equity requirements, ensuring the continuation of its listing on the Nasdaq Capital Market. The company exceeded the $2.5 million minimum stockholders’ equity threshold, as mandated by Nasdaq Listing Rule 5550(b)(1).
The decision follows a ruling from the Nasdaq Hearings Panel on February 25, 2025, confirming Traws’ compliance after a hearing in November 2024. This milestone comes alongside recent progress in Traws’ operational and scientific endeavors, particularly its pipeline of investigational antiviral treatments.
Key Developments
A financing round that closed on December 30, 2024, secured $20 million in gross proceeds, significantly bolstering the company’s financial foundation. These funds have enabled Traws to continue advancing its leading program targeting bird flu and influenza, which recently completed a Phase 1 trial. This effort is complemented by ongoing laboratory studies aimed at developing novel antiviral therapies.
Dr. Werner Cautreels, Chief Executive Officer of Traws Pharma, called 2025 a potentially pivotal year, as the company builds on its strengthened financial position and drives meaningful progress toward innovative treatments.
Monitoring Period
To ensure consistent compliance, Traws will remain under mandatory monitoring by the Nasdaq Hearings Panel until February 2026. Any failure to maintain the required stockholders’ equity during this timeframe would subject the company to immediate risk of delisting, though it would have the opportunity to request a new hearing.
With this compliance decision in hand, Traws is poised to advance its mission of delivering cutting-edge antiviral solutions that meet critical healthcare needs.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.